NCT07143409

Brief Summary

Fungal vascular graft and endograft infections (VGEIs) are rare but life-threatening infections. Best therapeutic management is unknown. This study retrospectively gathers fungal VGEIs from 12 university hospital centers in France over a 10 year's period in order to describe their epidemiology, clinical features, therapeutic management and outcomes. Focusing on Candida spp. VGEIs, we aim to determine prognosis factors associated with therapeutic management

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
12mo left

Started Jan 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress26%
Jan 2026May 2027

First Submitted

Initial submission to the registry

August 19, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 27, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Last Updated

December 16, 2025

Status Verified

December 1, 2025

Enrollment Period

1.3 years

First QC Date

August 19, 2025

Last Update Submit

December 9, 2025

Conditions

Vascular GraftingFungal Infection

Keywords

vascular graft infectionvascular endograft infectionfungiCandida

Outcome Measures

Primary Outcomes (1)

  • Rate of mortality

    Rate of all-cause mortality

    Year 1

Secondary Outcomes (4)

  • Rate of mortality

    Month 1

  • Fungal vascular graft and endograft infections-related mortality

    Month 1, Year 1

  • Rate of cure

    Year 1

  • Rate of sequelae

    Year 1

Interventions

epidemiology and medical treatment strategiesOTHER

Analysis of the epidemiology and medical and surgical treatment strategies for fungal IPEV in France between January 2013 and January 2023

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with fungal infection on a vascular sample

You may qualify if:

  • Patients aged ≥ 18 years old with diagnosis of vascular graft and endograft infections (VGEI) in accordance to MAGIC criteria with diagnosis of proven invasive fungal infection according to EORTC criteria.
  • No opposition to re-use data.

You may not qualify if:

  • Patient previously treated for fungal VGEI
  • Patient with suspected VGEI diagnosis based solely on prosthesis implantation in an infected site
  • Poor understanding of French.
  • Patient under legal protection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Bordeaux

Bordeaux, France

Location

MeSH Terms

Conditions

MycosesTorulopsis

Condition Hierarchy (Ancestors)

Bacterial Infections and MycosesInfections

Central Study Contacts

Mathilde Puges, MD

CONTACT

+335 56 79 55 36mathilde.puges@u-bordeaux.fr

Carole Vignals, MD

CONTACT

+335 56 79 55 36carole.vignals@aphp.fr

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2025

First Posted

August 27, 2025

Study Start

January 1, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2027

Last Updated

December 16, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)